Tags

Type your tag names separated by a space and hit enter

Experience with intraperitoneal insulin infusion from implantable programmable systems in type 1 (insulin-dependent) diabetes mellitus previously treated by external pumps.
Diabete Metab. 1993 Jul-Aug; 19(4):364-71.DM

Abstract

The feasibility of the continuous intraperitoneal insulin infusion from implantable programmable systems was evaluated in 17 Type 1 (insulin-dependent) diabetic patients currently treated by external pumps. Eight subjects were using a continuous subcutaneous insulin infusion (cumulated experience: 7.4 patients x years) and nine subjects had a cumulated experience of 61.4 patients x years of continuous intra peritoneal insulin delivery by external pumps. The two studied implantable systems (A and B) were delivering the same pH neutral surfactant-stabilized semi-synthetic human insulin, but at the respective concentrations of 400 units per ml in group A (n = 12) and of 100 units per ml in group B (n = 5), via a peritoneal catheter. The pump was implanted in a subcutaneous pocket created in the abdominal wall under general anesthesia. The reported trial of implantable programmable systems is 21 patient x years with an individual experience of 1.2 +/- 0.4 years (mean +/- SD). A sustained and stable glycaemic control was obtained, as indicated by the haemoglobin A1c: 7.4 +/- 1.3% (normal range: 4.3-6.1%), the mean blood glucose: 7.4 +/- 2.1 mM.l-1, the standard deviation of blood glucose values: 3.4 +/- 0.4 mM.l-1 and the percentages of 13.1 +/- 4.5% and 6.1 +/- 6.1% of blood glucose values respectively over 11 mM.l-1 and under 2.8 mM.l-1 after one year. The only metabolic event to occur was one episode of ketoacidosis secondary to a catheter obstruction. No hypoglycaemic coma occurred contrasting with incidences of 0.54 and 0.05 per patient x year during subcutaneous external and intraperitoneal pumps respectively (p < 0.02).(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Service d'Endocrinologie, Hôpital Lapeyronie, Montpellier, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

8293863

Citation

Renard, E, et al. "Experience With Intraperitoneal Insulin Infusion From Implantable Programmable Systems in Type 1 (insulin-dependent) Diabetes Mellitus Previously Treated By External Pumps." Diabete & Metabolisme, vol. 19, no. 4, 1993, pp. 364-71.
Renard E, Lauton D, Bonifacj C, et al. Experience with intraperitoneal insulin infusion from implantable programmable systems in type 1 (insulin-dependent) diabetes mellitus previously treated by external pumps. Diabete Metab. 1993;19(4):364-71.
Renard, E., Lauton, D., Bonifacj, C., Costalat, G., Jacques, D., Bringer, J., & Jaffiol, C. (1993). Experience with intraperitoneal insulin infusion from implantable programmable systems in type 1 (insulin-dependent) diabetes mellitus previously treated by external pumps. Diabete & Metabolisme, 19(4), 364-71.
Renard E, et al. Experience With Intraperitoneal Insulin Infusion From Implantable Programmable Systems in Type 1 (insulin-dependent) Diabetes Mellitus Previously Treated By External Pumps. Diabete Metab. 1993 Jul-Aug;19(4):364-71. PubMed PMID: 8293863.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Experience with intraperitoneal insulin infusion from implantable programmable systems in type 1 (insulin-dependent) diabetes mellitus previously treated by external pumps. AU - Renard,E, AU - Lauton,D, AU - Bonifacj,C, AU - Costalat,G, AU - Jacques,D, AU - Bringer,J, AU - Jaffiol,C, PY - 1993/7/1/pubmed PY - 2000/3/11/medline PY - 1993/7/1/entrez SP - 364 EP - 71 JF - Diabete & metabolisme JO - Diabete Metab VL - 19 IS - 4 N2 - The feasibility of the continuous intraperitoneal insulin infusion from implantable programmable systems was evaluated in 17 Type 1 (insulin-dependent) diabetic patients currently treated by external pumps. Eight subjects were using a continuous subcutaneous insulin infusion (cumulated experience: 7.4 patients x years) and nine subjects had a cumulated experience of 61.4 patients x years of continuous intra peritoneal insulin delivery by external pumps. The two studied implantable systems (A and B) were delivering the same pH neutral surfactant-stabilized semi-synthetic human insulin, but at the respective concentrations of 400 units per ml in group A (n = 12) and of 100 units per ml in group B (n = 5), via a peritoneal catheter. The pump was implanted in a subcutaneous pocket created in the abdominal wall under general anesthesia. The reported trial of implantable programmable systems is 21 patient x years with an individual experience of 1.2 +/- 0.4 years (mean +/- SD). A sustained and stable glycaemic control was obtained, as indicated by the haemoglobin A1c: 7.4 +/- 1.3% (normal range: 4.3-6.1%), the mean blood glucose: 7.4 +/- 2.1 mM.l-1, the standard deviation of blood glucose values: 3.4 +/- 0.4 mM.l-1 and the percentages of 13.1 +/- 4.5% and 6.1 +/- 6.1% of blood glucose values respectively over 11 mM.l-1 and under 2.8 mM.l-1 after one year. The only metabolic event to occur was one episode of ketoacidosis secondary to a catheter obstruction. No hypoglycaemic coma occurred contrasting with incidences of 0.54 and 0.05 per patient x year during subcutaneous external and intraperitoneal pumps respectively (p < 0.02).(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0338-1684 UR - https://www.unboundmedicine.com/medline/citation/8293863/Experience_with_intraperitoneal_insulin_infusion_from_implantable_programmable_systems_in_type_1__insulin_dependent__diabetes_mellitus_previously_treated_by_external_pumps_ DB - PRIME DP - Unbound Medicine ER -